1 / 27

Management of disease recurrence after renal transplantation

Management of disease recurrence after renal transplantation. Patrick Niaudet Néphrologie Pédiatrique Centre de référence des maladies rénales génétiques H ôpital Necker-Enfants Malades, Paris ESPN, September 2008. Recurrence of primary disease.

marvin
Download Presentation

Management of disease recurrence after renal transplantation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Management of disease recurrence after renal transplantation Patrick Niaudet Néphrologie Pédiatrique Centre de référence des maladies rénales génétiques Hôpital Necker-Enfants Malades, Paris ESPN, September 2008

  2. Recurrence of primary disease

  3. Recurrence of nephrotic syndrome after renal transplantation • Occurs in about 30% of patients with SRNS and FSGS • Extremely low rate of recurrence in genetic forms of the disease • Proteinuria is most often of rapid onset

  4. Recurrence of nephrotic syndrome after renal transplantation • Risk factors for recurrence : • duration of disease shorter than 3 years • disease starting after the age of 6 years • diffuse mesangial proliferation on initial biopsy • recurrence on a previous graft • Graft failure occurs in 60% of patients with recurrence • CsA does not prevent recurrence but improves graft survival

  5. Recurrence of nephrotic syndrome according to the age at onset of disease % with recurrence age > 6 years 54 age < 6 years 22 (p < 0.01) age < 3 years (n=41) 7 age < 1 year (n=15) 0 Enfants Malades

  6. Removal of circulating factor lowers protein excretion in recurrent NS P l a s m a e x c h a n g e 1 0 0 Pu P r o t e i n a b s o r p t i o n 8 0 6 0 4 0 2 0 Prett Tt Day 7 Day 15 Dantal et al, NEJM 1994, 330: 7

  7. Prophylactic plasma exchanges • Recurrence in 4 of 6 pts in the non prophylactic group • Recurrence in 5 of 15 pts in the prophylactic group • 7 recurrent pts received PE with remission in 6 (Ohta et al, Transplantation, 2001)

  8. Plasma exchanges plus cyclophosphamide • Dall’Amico et al (AJKD, 1999) • Sucessfull in 9 of 11 children • Persistent remission in 7 with a follow-up of 32 months • Cheong et al (NDT, 2000) • Complete remission in 3/6 • Partial remission in 3/6

  9. Rituximab failed to improve nephrotic syndrome in four adult renal transplant patients with early recurrent FSGS refractory or dependent on plasmapheresis Yabu JM et al AJT 2008; 8: 222-7

  10. Intravenous CsA for recurrent nephrotic syndrome after RT • Between March 1991 and July 2007, recurrence has occurred in 22 grafts in 21 children • CsA was immediately administered IV, at an initial dose of 3 mg/kg/d and the dose was adjusted in order to maintain whole blood levels above 250 ng/ml • Plasma exchanges, 2 to 10 sessions, in 9 patients Enfants Malades

  11. Intravenous CsA for recurrent nephrotic syndrome after RT • One pt with delayed recurrence (day 18) did not respond to IV CsA + PE • Among the 21 early recurrences (within the first week) : • 1 pt did not respond to IV CsA + PE • 3 pts showed partial remission (proteinuria without nephrotic syndrome) after IV CsA + ACEI • 17 pts (77%) entered into complete remission within 20 days (D12 to D40) • with CsA alone in 11 cases • with CsA + PE in 7 cases • 11 of the 17 pts are still in CR 1 to 14 years later

  12. Recurrence of NS after RT • Seems to be mediated by a circulating 50-kD plasma protein, which is bound to Ig • Identification of the protein ? • Clinical usefullness of the presence of the « permeability » factor ? • Living donor or cadaveric donor ? • Best therapy • Plasma exchanges ± cyclophosphamide • IV cyclosporine ± plasma exchanges • Others ?

  13. Atypical HUS • Mutations in genes of the complement pathway (50%) • Anti-CFH antibodies • Von Willebrand factor cleaving protease deficiency (ADAMTS13 gene mutation) • Defects of vitamine B12 metabolism • Idiopathic autosomal recessive disease • Idiopathic autosomal dominant disease

  14. Mutation Atypical HUS : French Pediatric Registry (Sellier-Leclerc et al, JASN 2007)

  15. Atypical HUS : posttransplant course • 24 grafts in 15 patients • 12 graft failures during the first year (50%) • 8 from thrombosis • 3 from recurrence • 1 from CMV • 4 graft failures later (recurrence in 2, rejection in 2) • 2 functioning grafts at 2yr despite recurrence • 6 grafts with good outcome 5 to 15 yr later (Sellier-Leclerc, JASN 2007)

  16. Atypical HUS : recurrence after RT Mutation Richards 2003 ; Fremeaux-Bacchi 2004, 2006, 2007 ; Kavanagh 2005 ; Bresin 2005 ; Caprioli 2006 ; Heinen 2006 ; Venables 2006 ; Nilsson 2007 ; Geelen 2007 ; Sellier-Leclerc 2007

  17. Possible therapy • FFP ± PE • Eculizumab (monoclonal antibody) • Binds to C5, inhibiting its clivage to C5a and C5b • Prevents the release of C5a and the formation of C5b-C9 • Reduces transfusion requirements in paroxysmal noctural hemoglobinuria (lack of GPI-linked-proteins that protect cells from complement-mediated attack)

  18. Atypical HUS with CFH mutation : results of liver transplantation • Initial experience with combined L+K (2) or L (1) but no plasma therapy : 2 deaths and 1 with neurological sequellae (Remuzzi, Cheong) • Combined L+K with extensive plasma therapy : 4 children with excellent outcome and no recurrence (Saland, Jalanko) • PE with FFP before surgery • FFP ± PE during surgery • Anticoagulation after surgery

  19. Consensus Conference(Bergame, Dec 2007)Indications for combined liver-renal or isolated liver transplantation • CFH mutation • First graft lost from recurrence • Another family member with the same mutation and who lost a graft from recurrence • Patient with a mutation reported to be associated with graft loss from recurrence • Not enough data for HUS associated with other complement mutations

  20. Conservative treatment of primary hyperoxaluria High fluid intake over 24h : 3l/m2 Solubilization of calcium oxalate : potassium citrate AGT coenzyme : Pyridoxine [G170R] Avoid surgical removal of calculs Low oxalate diet Oxalobacter formigenes (OxabactTM : 2 x 107 UFC/d) : ongoing trial

  21. Evolution of GFR in children with PH1 under conservative treatment 200 180 160 140 120 100 GFR (Schwartz formula) mL/mn/1.73m2 80 • GFR at initiation : 92 ml/mn • At last examination • Stable GFR 19/27pts • Decreased GFR 8/27pts • ESRF 4/27pts 60 40 20 0 0 24 48 72 96 120 144 168 192 216 240 time (months) (Société de Néphrologie Pédiatrique)

  22. Extra renal complications in PH1 Oxalate accumulates in tissues when plasma oxalate reaches 50mol/l 4 to 8 mmol of oxalate are produced every day • bone disease • retinal deposits with amblyopia • conduction system abnormalities • cardiomyopathy • artery calcifications and ischemia • livedo reticularis , gangrene • polyneuritis

  23. Transplantation strategy (P. Cochat)

  24. Management of primary hyperoxaluria • The best treatment of oxalosis is conservative and preventive when possible • A careful protocol must be applied and maintained for preventing recurrence on the graft • The most important point is to maintain high urine output after renal transplantation (low oxalate concentration) • Dialysis is indicated only in case of oliguria

  25. 2000 1750 1500 1250 1000 750 500 250 0 0 500 1000 1500 2000 24 h Oxaluria in 3 children after liver/ kidney transplantation µmol/ day Days post grafting

  26. Evolution of extra renal complications after liver-kidney transplantation • Bone disease improves very slowly but complete healing was reported after several years Toussaint et al Am J Kidney Dis 1993 21 54 • Conduction system abnormalities and cardiomyopathy may rapidly be reversed after some weeks Rodby et al. Am J Med 1991 90 498 Fyfe et al. Am J Cardiol 1995 75 210

  27. Conclusion • Recurrent disease in a renal transplant remains an important cause of chronic allograft dysfunction and graft failure • Patients and their families should be informed of the recurrence risk, potential therapeutic options and prognosis • The indication of retransplantation when a primary graft has been lost to recurrence is a difficult issue

More Related